Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novavax IncfiledCriticalNovavax Inc
Publication of AR121151A1publicationCriticalpatent/AR121151A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
En el presente documento se divulgan proteínas de la espícula (S) de coronavirus y nanopartículas que las comprenden, que son adecuadas para su uso en vacunas. Las nanopartículas presentan antígenos de patógenos rodeados y asociados con un centro detergente, que da como resultado una estabilidad potenciada y buena inmunogenia. También se divulgan dosificaciones, formulaciones, y métodos para preparar las vacunas y nanopartículas.Disclosed herein are coronavirus spike (S) proteins and nanoparticles comprising them, which are suitable for use in vaccines. The nanoparticles present pathogen antigens surrounded and associated with a detergent center, resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
ARP210100201A2020-01-272021-01-27
FORMULATIONS FOR VACCINE AGAINST CORONAVIRUS
AR121151A1
(en)
AN IMMUNOGENIC COMPOSITION THAT HAS IMPROVED STABILITY, POTENTIAL IMMUNOGENICITY AND REDUCED REACTOGENICITY AND PROCESS FOR THE PREPARATION OF THE SAME
A VACCINE BASED ON SURFACE ANTIGENS AGAINST INFLUENZA, A METHOD FOR PREPARING IT, AND A METHOD FOR PREPARING SURFACE ANTIGEN PROTEINS FROM PROPAGATED INFLUENZA VIRUSES ON AN ANIMAL CELL CULTURE
VIROSOMIC PREPARATION, USE OF A VIROSOMAL PREPARATION, KIT, AND METHODS TO VACCINATE A HUMAN AGAINST INFLUENZA INFECTIONS, AND TO VACCINATE INDIVIDUALS MAMMALIANS AGAINST INFLUENZA INFECTIONS